Cogent Biosciences, Inc. (NASDAQ:COGT) Holdings Trimmed by Jane Street Group LLC

Jane Street Group LLC trimmed its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) by 55.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 111,863 shares of the technology company’s stock after selling 136,681 shares during the quarter. Jane Street Group LLC owned 0.10% of Cogent Biosciences worth $1,208,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Point72 Asset Management L.P. raised its position in shares of Cogent Biosciences by 124.5% during the second quarter. Point72 Asset Management L.P. now owns 14,986,398 shares of the technology company’s stock worth $126,335,000 after purchasing an additional 8,310,150 shares during the period. Deerfield Management Company L.P. Series C increased its stake in Cogent Biosciences by 144.0% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,744,263 shares of the technology company’s stock worth $31,564,000 after purchasing an additional 2,209,918 shares in the last quarter. FMR LLC raised its holdings in Cogent Biosciences by 8.1% during the 3rd quarter. FMR LLC now owns 8,319,411 shares of the technology company’s stock worth $89,850,000 after buying an additional 625,743 shares during the period. Walleye Capital LLC purchased a new stake in Cogent Biosciences during the third quarter valued at about $6,019,000. Finally, Sofinnova Investments Inc. boosted its holdings in shares of Cogent Biosciences by 15.5% in the second quarter. Sofinnova Investments Inc. now owns 2,773,286 shares of the technology company’s stock worth $23,379,000 after buying an additional 372,515 shares during the period.

Analyst Ratings Changes

A number of research firms have recently issued reports on COGT. Needham & Company LLC lowered shares of Cogent Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Citigroup boosted their target price on shares of Cogent Biosciences from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. JPMorgan Chase & Co. raised their target price on Cogent Biosciences from $19.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating on shares of Cogent Biosciences in a report on Wednesday, December 11th. Finally, Robert W. Baird increased their price objective on Cogent Biosciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, September 5th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Cogent Biosciences Trading Down 1.7 %

NASDAQ COGT opened at $7.74 on Monday. The company has a market capitalization of $854.98 million, a PE ratio of -3.12 and a beta of 1.70. Cogent Biosciences, Inc. has a 1-year low of $4.28 and a 1-year high of $12.61. The firm’s fifty day simple moving average is $9.68 and its 200-day simple moving average is $9.75.

Cogent Biosciences (NASDAQ:COGT) last issued its earnings results on Tuesday, November 12th. The technology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same period in the prior year, the business earned ($0.64) earnings per share. As a group, analysts predict that Cogent Biosciences, Inc. will post -2.42 EPS for the current year.

Cogent Biosciences Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.